Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

NCT05311618 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer
Breast Cancer
Gastric Cancer
Non Small Cell Lung Cancer
Cervical Cancer
Endocervical Cancer
Squamous Cell Carcinoma of Head and Neck
Bladder Urothelial Cancer
Colorectal Cancer
Esophageal Cancer
Ovarian Cancer
Renal Cell Carcinoma
Prostate Cancer
Melanoma
Mesothelioma
Cholangiocarcinoma

Interventions

DRUG: NGM438
DRUG: Pembrolizumab (KEYTRUDA ®)

Sponsor

NGM Biopharmaceuticals, Inc

Collaborators

[object Object]